240 related articles for article (PubMed ID: 19305397)
1. Molecular docking and ligand specificity in fragment-based inhibitor discovery.
Chen Y; Shoichet BK
Nat Chem Biol; 2009 May; 5(5):358-64. PubMed ID: 19305397
[TBL] [Abstract][Full Text] [Related]
2. Docking for fragment inhibitors of AmpC beta-lactamase.
Teotico DG; Babaoglu K; Rocklin GJ; Ferreira RS; Giannetti AM; Shoichet BK
Proc Natl Acad Sci U S A; 2009 May; 106(18):7455-60. PubMed ID: 19416920
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase.
Babaoglu K; Simeonov A; Irwin JJ; Nelson ME; Feng B; Thomas CJ; Cancian L; Costi MP; Maltby DA; Jadhav A; Inglese J; Austin CP; Shoichet BK
J Med Chem; 2008 Apr; 51(8):2502-11. PubMed ID: 18333608
[TBL] [Abstract][Full Text] [Related]
4. Increasing chemical space coverage by combining empirical and computational fragment screens.
Barelier S; Eidam O; Fish I; Hollander J; Figaroa F; Nachane R; Irwin JJ; Shoichet BK; Siegal G
ACS Chem Biol; 2014 Jul; 9(7):1528-35. PubMed ID: 24807704
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel Cyclophilin D inhibitors starting from three dimensional fragments with millimolar potencies.
Grädler U; Schwarz D; Blaesse M; Leuthner B; Johnson TL; Bernard F; Jiang X; Marx A; Gilardone M; Lemoine H; Roche D; Jorand-Lebrun C
Bioorg Med Chem Lett; 2019 Dec; 29(23):126717. PubMed ID: 31635932
[TBL] [Abstract][Full Text] [Related]
6. Deconstructing fragment-based inhibitor discovery.
Babaoglu K; Shoichet BK
Nat Chem Biol; 2006 Dec; 2(12):720-3. PubMed ID: 17072304
[TBL] [Abstract][Full Text] [Related]
7. Fragment-Based Discovery and Optimization of Enzyme Inhibitors by Docking of Commercial Chemical Space.
Rudling A; Gustafsson R; Almlöf I; Homan E; Scobie M; Warpman Berglund U; Helleday T; Stenmark P; Carlsson J
J Med Chem; 2017 Oct; 60(19):8160-8169. PubMed ID: 28929756
[TBL] [Abstract][Full Text] [Related]
8. Validation of the AmpC β-lactamase binding site and identification of inhibitors with novel scaffolds.
Chan FY; Neves MA; Sun N; Tsang MW; Leung YC; Chan TH; Abagyan R; Wong KY
J Chem Inf Model; 2012 May; 52(5):1367-75. PubMed ID: 22559726
[TBL] [Abstract][Full Text] [Related]
9. Frag4Lead: growing crystallographic fragment hits by catalog using fragment-guided template docking.
Metz A; Wollenhaupt J; Glöckner S; Messini N; Huber S; Barthel T; Merabet A; Gerber HD; Heine A; Klebe G; Weiss MS
Acta Crystallogr D Struct Biol; 2021 Sep; 77(Pt 9):1168-1182. PubMed ID: 34473087
[TBL] [Abstract][Full Text] [Related]
10. Active-Site Druggability of Carbapenemases and Broad-Spectrum Inhibitor Discovery.
Torelli NJ; Akhtar A; DeFrees K; Jaishankar P; Pemberton OA; Zhang X; Johnson C; Renslo AR; Chen Y
ACS Infect Dis; 2019 Jun; 5(6):1013-1021. PubMed ID: 30942078
[TBL] [Abstract][Full Text] [Related]
11. Structure-based discovery of a novel, noncovalent inhibitor of AmpC beta-lactamase.
Powers RA; Morandi F; Shoichet BK
Structure; 2002 Jul; 10(7):1013-23. PubMed ID: 12121656
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design and in-parallel synthesis of inhibitors of AmpC beta-lactamase.
Tondi D; Powers RA; Caselli E; Negri MC; Blázquez J; Costi MP; Shoichet BK
Chem Biol; 2001 Jun; 8(6):593-611. PubMed ID: 11410378
[TBL] [Abstract][Full Text] [Related]
13. Structure-based enhancement of boronic acid-based inhibitors of AmpC beta-lactamase.
Weston GS; Blázquez J; Baquero F; Shoichet BK
J Med Chem; 1998 Nov; 41(23):4577-86. PubMed ID: 9804697
[TBL] [Abstract][Full Text] [Related]
14. Differentiation of AmpC beta-lactamase binders vs. decoys using classification kNN QSAR modeling and application of the QSAR classifier to virtual screening.
Hsieh JH; Wang XS; Teotico D; Golbraikh A; Tropsha A
J Comput Aided Mol Des; 2008 Sep; 22(9):593-609. PubMed ID: 18338225
[TBL] [Abstract][Full Text] [Related]
15. Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B.
Doman TN; McGovern SL; Witherbee BJ; Kasten TP; Kurumbail R; Stallings WC; Connolly DT; Shoichet BK
J Med Chem; 2002 May; 45(11):2213-21. PubMed ID: 12014959
[TBL] [Abstract][Full Text] [Related]
16. Structure-based approach for binding site identification on AmpC beta-lactamase.
Powers RA; Shoichet BK
J Med Chem; 2002 Jul; 45(15):3222-34. PubMed ID: 12109906
[TBL] [Abstract][Full Text] [Related]
17. Ultra-large library docking for discovering new chemotypes.
Lyu J; Wang S; Balius TE; Singh I; Levit A; Moroz YS; O'Meara MJ; Che T; Algaa E; Tolmachova K; Tolmachev AA; Shoichet BK; Roth BL; Irwin JJ
Nature; 2019 Feb; 566(7743):224-229. PubMed ID: 30728502
[TBL] [Abstract][Full Text] [Related]
18. Fragment-based screening by X-ray crystallography, MS and isothermal titration calorimetry to identify PNMT (phenylethanolamine N-methyltransferase) inhibitors.
Drinkwater N; Vu H; Lovell KM; Criscione KR; Collins BM; Prisinzano TE; Poulsen SA; McLeish MJ; Grunewald GL; Martin JL
Biochem J; 2010 Oct; 431(1):51-61. PubMed ID: 20642456
[TBL] [Abstract][Full Text] [Related]
19. Fragments as Novel Starting Points for tRNA-Guanine Transglycosylase Inhibitors Found by Alternative Screening Strategies.
Hassaan E; Eriksson PO; Geschwindner S; Heine A; Klebe G
ChemMedChem; 2020 Feb; 15(3):324-337. PubMed ID: 31808981
[TBL] [Abstract][Full Text] [Related]
20. Structure-based optimization of cephalothin-analogue boronic acids as beta-lactamase inhibitors.
Morandi S; Morandi F; Caselli E; Shoichet BK; Prati F
Bioorg Med Chem; 2008 Feb; 16(3):1195-205. PubMed ID: 17997318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
